Risk factor
Negligible price volatility
Profitability factor
Greatly overvalued vs peers
About
HealthCare Global Enterprises Limited, founded in 1989 and headquartered in Bengaluru, India, delivers comprehensive healthcare services with a primary focus on oncology. The company offers a full spectrum of cancer care, from diagnosis to various treatment modalities such as radiation therapy, medical oncology, and surgical procedures. Beyond its core cancer services, HCG also operates in the field of fertility and reproductive medicine under its Milann brand. This includes services like assisted reproduction, gynecological endoscopy, and fertility preservation. The enterprise further manages four multi-specialty hospitals: three branded HCG facilities located in Ahmedabad, Bhavnagar, and Rajkot in Gujarat, and one in Hubli, Karnataka, operated under a management contract. These hospitals cater to diverse medical specialities including cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, pulmonary care, and critical care. Additionally, HealthCare Global provides medical diagnostic services, offering scientific testing and consultancy for the pharmaceutical and broader medical industries. As of March 31, 2021, its extensive network comprised 23 cancer centers throughout India, featuring a center of excellence in Bengaluru, alongside two independent diagnostic centers and one day-care chemotherapy unit. The company also maintains an international presence with a cancer center established in Africa.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, of fair va
Target Price
The average target price of HCG.NS is 801 and suggests 16% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre